Lebensbeendende Handlungen (Ethik, Medizin und Recht zur Grenze von ‚Töten‘ und ‚Sterbenlassen‘) (German Edition)
List Price:
$59.99
- Availability: Confirm prior to ordering
- Branding: minimum 50 pieces (add’l costs below)
- Check Freight Rates (branded products only)
Branding Options (v), Availability & Lead Times
- 1-Color Imprint: $2.00 ea.
- Promo-Page Insert: $2.50 ea. (full-color printed, single-sided page)
- Belly-Band Wrap: $2.50 ea. (full-color printed)
- Set-Up Charge: $45 per decoration
- Availability: Product availability changes daily, so please confirm your quantity is available prior to placing an order.
- Branded Products: allow 10 business days from proof approval for production. Branding options may be limited or unavailable based on product design or cover artwork.
- Unbranded Products: allow 3-5 business days for shipping. All Unbranded items receive FREE ground shipping in the US. Inquire for international shipping.
- RETURNS/CANCELLATIONS: All orders, branded or unbranded, are NON-CANCELLABLE and NON-RETURNABLE once a purchase order has been received.
Product Details
Author:
Franz-Josef Bormann
Format:
Paperback
Pages:
857
Publisher:
De Gruyter (November 19, 2018)
Language:
German
Audience:
Professional and scholarly
ISBN-13:
9783110636789
ISBN-10:
3110636786
Weight:
45.76oz
Dimensions:
6.1" x 9.06"
File:
TWO RIVERS-PERSEUS-Metadata_Only_Perseus_Distribution_Customer_Group_Metadata_20260407163709-20260408.xml
Folder:
TWO RIVERS
List Price:
$59.99
Country of Origin:
Germany
As low as:
$51.59
Publisher Identifier:
P-PER
Discount Code:
C
Pub Discount:
60
Imprint:
De Gruyter
Overview
Der Begriff der ‚lebensbeendenden Handlungen‘ umfasst ein breites Spektrum von Praktiken, das von unstreitigen Tötungsdelikten bis hin zu verschiedenen Formen der medizinischen Therapiebegrenzung reicht. Die interdisziplinären Beiträge des vorliegenden Bandes versuchen, die ethisch und rechtlich entscheidende Grenze zwischen den Handlungstypen des ‚Tötens‘ und des ‚Sterbenlassens‘ genauer zu rekonstruieren, um die Handlungssicherheit klinischer Akteure zu erhöhen.
